Skip to main content

Table 3 Logistic regression analysis for predicting CSPCa

From: 68Ga-PSMA PET/CT-based multivariate model for highly accurate and noninvasive diagnosis of clinically significant prostate cancer in the PSA gray zone

 

Univariate analysis

 

Multivariate analysis

 

OR (95% CI)

P value

 

OR (95% CI)

P value

Age (years)

1.05 (0.98–1.13)

0.204

 

-

-

PSA

1.17 (0.92–1.49)

0.209

 

-

-

PV (ml)

0.95 (0.92–0.98)

0.002*

 

0.95 (0.91-1.00)

0.032*

PSAD (ng/ml2)

   

-

-

<0.15

reference

-

 

-

-

≥0.15

12.71 (3.31–48.76)

< 0.001*

 

-

-

FPSA/TPSA

0.00 (0.00-0.03)

0.005*

 

0.00 (0.00-0.05)

0.016*

SUVmax

1.50 (1.23–1.83)

< 0.001*

 

1.73 (1.33–2.25)

< 0.001*

  1. CSPCa, clinically significant prostate cancer; PSA, prostate-specific antigen; PV, prostate volume; PSAD, prostate-specific antigen density; TPSA, total prostate-specific antigen; FPSA, free prostate-specific antigen; SUVmax, maximum standardized uptake values
  2. * p < 0.05
Back to article page

Cancer Imaging

ISSN: 1470-7330

Contact us